Research study Program year 2020 Source: CMS Open Payments

Evolocumab in Patients with ST Elevation Myocardial Infarction: A Double-blind, Prospective, Randomized Placebo-Controlled Study

Research payments

$1,317,567

7 payments

Through program year 2020, $1,317,567 in research payments was reported against Evolocumab in Patients with ST Elevation Myocardial Infarction: A Double-blind, Prospective, Randomized Placebo-Controlled Study, across 7 payments, paid by Amgen Inc..

Paid by: Amgen Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$550,144	4
2019	Research	$767,423	3

Breakdown

Who paid Research payments · program years 2019–2020

Amgen Inc. $1,317,567 7 payments

Who received the money Research payments · program years 2019–2020

Johns Hopkins Univ Organisation paid for research $1,283,269 2 payments
Johns Hopkins Univ Sch Of Med Organisation paid for research $16,800 2 payments
Johns Hopkins Bayview Medical Ctr Organisation paid for research $10,668 1 payment
Johns Hopkins University School Of Medicine Organisation paid for research $5,029 1 payment
Johns Hopkins Bayview Med. Ctr. Teaching hospital · MD $1,800 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

1 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

Thorsten Leucker Baltimore, MD Named on 7 payments

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.